VIR Fundamental Analysis - VIR BIOTECHNOLOGY INC

Name: VIR BIOTECHNOLOGY INC (VIR) Stock
Brand: VIR BIOTECHNOLOGY INC
Rating: 4.5 (3 reviews)

Fundamental Rating

Taking everything into account, VIR scores 3 out of 10 in our fundamental rating. VIR was compared to 533 industry peers in the Biotechnology industry. VIR has a great financial health rating, but its profitability evaluates not so good. VIR is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

VIR had negative earnings in the past year.

VIR had a negative operating cash flow in the past year.

In multiple years VIR reported negative net income over the last 5 years.

In the past 5 years VIR reported 4 times negative operating cash flow.

1.2 Ratios

VIR has a Return On Assets (-46.14%) which is in line with its industry peers.

VIR has a better Return On Equity (-58.07%) than 62.10% of its industry peers.

		Industry Rank	Sector Rank
ROA	-46.14%
ROE	-58.07%
ROIC	N/A

ROA(3y)-16.99%

ROA(5y)-11.28%

ROE(3y)-19.74%

ROE(5y)-12.79%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of VIR (96.08%) is better than 95.50% of its industry peers.

VIR's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for VIR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.08%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.7%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

VIR does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, VIR has more shares outstanding

The number of shares outstanding for VIR has been increased compared to 5 years ago.

There is no outstanding debt for VIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

VIR has an Altman-Z score of -0.32. This is a bad value and indicates that VIR is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -0.32, VIR is in the better half of the industry, outperforming 60.98% of the companies in the same industry.

VIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-0.32

ROIC/WACCN/A

WACC8.76%

2.3 Liquidity

VIR has a Current Ratio of 7.01. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 7.01, VIR is in the better half of the industry, outperforming 69.79% of the companies in the same industry.

VIR has a Quick Ratio of 7.01. This indicates that VIR is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 7.01, VIR is in the better half of the industry, outperforming 69.98% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.01
Quick Ratio	7.01

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

VIR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.91%.

The Revenue for VIR has decreased by -13.90% in the past year. This is quite bad

The Revenue has been growing by 55.74% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)7.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25%

Revenue 1Y (TTM)-13.9%

Revenue growth 3Y-59.24%

Revenue growth 5Y55.74%

Sales Q2Q%-89.92%

3.2 Future

VIR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.23% yearly.

VIR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.82% yearly.

EPS Next Y13.12%

EPS Next 2Y11.82%

EPS Next 3Y10.45%

EPS Next 5Y10.23%

Revenue Next Year-83.95%

Revenue Next 2Y-56.99%

Revenue Next 3Y-35.89%

Revenue Next 5Y3.82%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

VIR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year VIR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y11.82%

EPS Next 3Y10.45%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

VIR does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VIR BIOTECHNOLOGY INC

NASDAQ:VIR (11/20/2025, 3:16:26 PM)

5.525

+0.08 (+1.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-05 2025-11-05/amc

Earnings (Next)02-24 2026-02-24/amc

Inst Owners67.6%

Inst Owner Change-5.05%

Ins Owners1.12%

Ins Owner Change-1.71%

Market Cap767.53M

Revenue(TTM)74.20M

Net Income(TTM)-550.23M

Analysts82.86

Price Target17.57 (218.01%)

Short Float %9.03%

Short Ratio7.12

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-6.87%

Min EPS beat(2)-9.48%

Max EPS beat(2)-4.26%

EPS beat(4)1

Avg EPS beat(4)-11.67%

Min EPS beat(4)-46.72%

Max EPS beat(4)13.76%

EPS beat(8)3

Avg EPS beat(8)1.33%

EPS beat(12)4

Avg EPS beat(12)48.76%

EPS beat(16)7

Avg EPS beat(16)213.56%

Revenue beat(2)0

Avg Revenue beat(2)-60.45%

Min Revenue beat(2)-65.06%

Max Revenue beat(2)-55.84%

Revenue beat(4)1

Avg Revenue beat(4)-31.9%

Min Revenue beat(4)-65.06%

Max Revenue beat(4)50.52%

Revenue beat(8)3

Avg Revenue beat(8)18.98%

Revenue beat(12)5

Avg Revenue beat(12)13.12%

Revenue beat(16)7

Avg Revenue beat(16)5.49%

PT rev (1m)0%

PT rev (3m)-2.29%

EPS NQ rev (1m)0%

EPS NQ rev (3m)1.21%

EPS NY rev (1m)0%

EPS NY rev (3m)-6.19%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-19.56%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-34.96%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	40.4
P/FCF	N/A
P/OCF	N/A
P/B	0.81
P/tB	0.83
EV/EBITDA	N/A

EPS(TTM)-3.61

EYN/A

EPS(NY)-2.86

Fwd EYN/A

FCF(TTM)-3.36

FCFYN/A

OCF(TTM)-3.29

OCFYN/A

SpS0.14

BVpS6.82

TBVpS6.64

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-46.14%
ROE	-58.07%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	96.08%
FCFM	N/A

ROA(3y)-16.99%

ROA(5y)-11.28%

ROE(3y)-19.74%

ROE(5y)-12.79%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.7%

GM growth 5YN/A

F-Score2

Asset Turnover0.02

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	77.21%
Cap/Sales	47%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.01
Quick Ratio	7.01
Altman-Z	-0.32

F-Score2

WACC8.76%

ROIC/WACCN/A

Cap/Depr(3y)387.02%

Cap/Depr(5y)331.46%

Cap/Sales(3y)13.03%

Cap/Sales(5y)9.92%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)7.91%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25%

EPS Next Y13.12%

EPS Next 2Y11.82%

EPS Next 3Y10.45%

EPS Next 5Y10.23%

Revenue 1Y (TTM)-13.9%

Revenue growth 3Y-59.24%

Revenue growth 5Y55.74%

Sales Q2Q%-89.92%

Revenue Next Year-83.95%

Revenue Next 2Y-56.99%

Revenue Next 3Y-35.89%

Revenue Next 5Y3.82%

EBIT growth 1Y-11.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year19.71%

EBIT Next 3Y7.47%

EBIT Next 5Y7.12%

FCF growth 1Y-13.81%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-26.4%

OCF growth 3YN/A

OCF growth 5YN/A

VIR BIOTECHNOLOGY INC / VIR FAQ

What is the fundamental rating for VIR stock?

ChartMill assigns a fundamental rating of 3 / 10 to VIR.

Can you provide the valuation status for VIR BIOTECHNOLOGY INC?

ChartMill assigns a valuation rating of 0 / 10 to VIR BIOTECHNOLOGY INC (VIR). This can be considered as Overvalued.

What is the profitability of VIR stock?

VIR BIOTECHNOLOGY INC (VIR) has a profitability rating of 2 / 10.

What is the expected EPS growth for VIR BIOTECHNOLOGY INC (VIR) stock?

The Earnings per Share (EPS) of VIR BIOTECHNOLOGY INC (VIR) is expected to grow by 13.12% in the next year.

VIR BIOTECHNOLOGY INC (VIR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

VIR BIOTECHNOLOGY INC / VIR FAQ

What is the fundamental rating for VIR stock?

Can you provide the valuation status for VIR BIOTECHNOLOGY INC?

What is the profitability of VIR stock?

What is the expected EPS growth for VIR BIOTECHNOLOGY INC (VIR) stock?